Foghorn Therapeutics Inc. Research and Development Expense
Foghorn Therapeutics Inc. (FHTX) reported Research and Development Expense of $18.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Foghorn Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $18.52M, a 15.00% decline year-over-year.
- Foghorn Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $18.26M, a 15.57% decline year-over-year.
- Foghorn Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $22.05M, a 7.50% increase year-over-year.
- Foghorn Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $20.00M, a 18.98% decline year-over-year.
- Foghorn Therapeutics Inc. research and development expense for fiscal 2025 was $85.47M, a 9.59% decline from fiscal 2024.
- Foghorn Therapeutics Inc. research and development expense for fiscal 2024 was $94.53M, a 13.82% decline from fiscal 2023.
- Foghorn Therapeutics Inc. research and development expense for fiscal 2023 was $109.69M, a 3.85% increase from fiscal 2022.
- Foghorn Therapeutics Inc. research and development expense for fiscal 2022 was $105.62M, a 31.49% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.52M 10-Q · filed 2026-08-06 | $36.78M 10-Q · filed 2026-08-06 | $58.83M derived: sum of 3 quarters · filed 2026-08-06 | $78.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.26M 10-Q · filed 2026-05-07 | $40.30M derived: sum of 2 quarters · filed 2026-05-07 | $60.31M derived: sum of 3 quarters · filed 2026-05-07 | $82.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $22.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $42.05M derived: sum of 2 quarters · filed 2026-03-11 | $63.84M derived: sum of 3 quarters · filed 2026-08-06 | $85.47M 10-K · filed 2026-03-11 |
| 2025-09-30 | $20.00M 10-Q · filed 2025-11-05 | $41.79M derived: sum of 2 quarters · filed 2026-08-06 | $63.42M 10-Q · filed 2025-11-05 | $83.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $21.79M 10-Q · filed 2026-08-06 | $43.42M 10-Q · filed 2026-08-06 | $63.93M derived: sum of 3 quarters · filed 2026-08-06 | $88.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $21.63M 10-Q · filed 2026-05-07 | $42.13M derived: sum of 2 quarters · filed 2026-05-07 | $66.82M derived: sum of 3 quarters · filed 2026-05-07 | $90.62M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $20.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $45.20M derived: sum of 2 quarters · filed 2026-03-11 | $68.99M derived: sum of 3 quarters · filed 2026-03-11 | $94.53M 10-K · filed 2026-03-11 |
| 2024-09-30 | $24.69M 10-Q · filed 2025-11-05 | $48.49M derived: sum of 2 quarters · filed 2025-11-05 | $74.02M 10-Q · filed 2025-11-05 | $98.22M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $23.80M 10-Q · filed 2025-08-05 | $49.33M 10-Q · filed 2025-08-05 | $73.54M derived: sum of 3 quarters · filed 2025-08-05 | $99.79M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $25.53M 10-Q · filed 2025-05-14 | $49.74M derived: sum of 2 quarters · filed 2025-05-14 | $75.99M derived: sum of 3 quarters · filed 2025-05-14 | $105.24M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $24.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $50.46M derived: sum of 2 quarters · filed 2025-03-06 | $79.70M derived: sum of 3 quarters · filed 2025-03-06 | $109.69M 10-K · filed 2025-03-06 |
| 2023-09-30 | $26.25M 10-Q · filed 2024-11-04 | $55.50M derived: sum of 2 quarters · filed 2024-11-04 | $85.48M 10-Q · filed 2024-11-04 | $113.69M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $29.25M 10-Q · filed 2024-08-08 | $59.23M 10-Q · filed 2024-08-08 | $87.44M derived: sum of 3 quarters · filed 2024-08-08 | $114.37M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $29.98M 10-Q · filed 2024-05-06 | $58.19M derived: sum of 2 quarters · filed 2024-05-06 | $85.12M derived: sum of 3 quarters · filed 2024-05-06 | $111.09M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $28.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $55.14M derived: sum of 2 quarters · filed 2024-03-07 | $81.11M derived: sum of 3 quarters · filed 2024-03-07 | $105.62M 10-K · filed 2024-03-07 |
| 2022-09-30 | $26.93M 10-Q · filed 2023-11-02 | $52.90M derived: sum of 2 quarters · filed 2023-11-02 | $77.41M 10-Q · filed 2023-11-02 | $99.87M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $25.97M 10-Q · filed 2023-08-04 | $50.48M 10-Q · filed 2023-08-04 | $72.94M derived: sum of 3 quarters · filed 2023-08-04 | $93.44M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $24.51M 10-Q · filed 2023-05-08 | $46.97M derived: sum of 2 quarters · filed 2023-05-08 | $67.47M derived: sum of 3 quarters · filed 2023-05-08 | $86.11M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $22.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $42.96M derived: sum of 2 quarters · filed 2023-03-09 | $61.60M derived: sum of 3 quarters · filed 2023-03-09 | $80.33M 10-K · filed 2023-03-09 |
| 2021-09-30 | $20.49M 10-Q · filed 2022-11-08 | $39.14M derived: sum of 2 quarters · filed 2022-11-08 | $57.86M 10-Q · filed 2022-11-08 | $74.33M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $18.64M 10-Q · filed 2022-08-09 | $37.37M 10-Q · filed 2022-08-09 | $53.84M derived: sum of 3 quarters · filed 2022-08-09 | $69.95M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $18.73M 10-Q · filed 2022-05-09 | $35.20M derived: sum of 2 quarters · filed 2022-08-09 | $51.31M derived: sum of 3 quarters · filed 2022-08-09 | $64.94M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $16.47M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $32.58M derived: sum of 2 quarters · filed 2022-08-09 | $46.21M derived: sum of 3 quarters · filed 2022-08-09 | $57.72M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $16.11M 10-Q · filed 2021-11-09 | $29.74M derived: sum of 2 quarters · filed 2021-11-09 | $41.24M 10-Q · filed 2021-11-09 | $54.76M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $13.63M 10-Q · filed 2021-08-10 | $25.13M 10-Q · filed 2021-08-10 | $38.65M derived: sum of 3 quarters · filed 2021-08-10 | $49.94M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $11.50M 10-Q · filed 2021-05-11 | $25.02M derived: sum of 2 quarters · filed 2021-05-11 | $36.31M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $24.81M derived: sum of 2 quarters · filed 2021-03-18 | $44.36M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $11.29M 10-Q · filed 2020-12-04 | $30.84M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |